Hydroxyurea vs Interferon: Which Is Right for ET Patients?

Choosing a long-term treatment for a chronic blood cancer like Essential Thrombocythemia (ET) can be stressful. The primary goal of treatment is to prevent thrombosis (blood clots) and control symptoms. Not everyone with ET needs cytoreductive (cell-reducing) medication; younger patients without a history of blood clots are often managed with just low-dose aspirin and careful observation ^[1]. However, if you are considered “high-risk”—usually because you are over 60, have had a prior blood clot, or have certain cardiovascular risks or severe symptoms—your hematologist will likely recommend a cytoreductive therapy to lower your platelet count ^[2].

The two most common first-line options are Hydroxyurea and Pegylated Interferon (often known by the brand name Pegasys, though its use for ET is off-label in many regions) ^[3]. Neither drug cures the disease, and neither should be stopped or adjusted without your doctor’s guidance. Both are effective at controlling blood counts ^[4]. The choice depends on your age, medical history, reproductive plans, and personal preferences ^[2].

How They Work and How They Are Taken

• Hydroxyurea (HU) is an oral chemotherapy pill. It works by temporarily slowing down DNA replication, which reduces the overproduction of all blood cells in the bone marrow ^[5]. Your doctor will individualize your dose (often daily or a few times a week) based on your lab results, and you should never change this schedule yourself ^[6].
• Pegylated Interferon alfa-2a is given as a subcutaneous injection (a small shot under the skin) ^[7]. While its full mechanism is not completely understood, it is a synthetic version of an immune protein that suppresses abnormal blood-cell production ^[8]. Like HU, the exact dose and frequency (often weekly or biweekly) are strictly determined by your hematologist based on how your body responds ^[7].

Side Effects and Tolerability

Tolerability varies greatly, and side effects are a major factor in deciding which drug is right for you.

• Hydroxyurea: Generally well-tolerated by many patients. The most common issues are cytopenias (lowering your white or red blood cells too much) and skin or nail changes ^[9]. Some patients develop mouth ulcers or painful skin ulcers on their lower legs ^[9]. With decades of prolonged use, HU is associated with an increased risk of non-melanoma skin cancers, so strict sun protection and regular dermatology checks are highly recommended ^[9].
• Pegylated Interferon: Commonly causes fatigue, muscle aches, and mild flu-like symptoms ^[10]. It can also trigger autoimmune problems, thyroid dysfunction, and mood changes, including depression ^[4].

In a major randomized trial comparing the two drugs in “treatment-naive” (previously untreated) high-risk ET and Polycythemia Vera patients, severe or medically significant side effects (referred to as Grade 3 or Grade 4 events) were more common with interferon (46%) than with hydroxyurea (28%) ^[4]. Because of these side effects, some patients find they cannot stay on interferon long-term, though your doctor can often adjust the dose to help manage symptoms ^[11].

Safety Monitoring and Warning Signs

Regardless of which medication you choose, you will require regular monitoring:

• Hydroxyurea Monitoring: Frequent blood counts, kidney function tests, and periodic skin examinations.
• Interferon Monitoring: Frequent blood counts, liver tests, thyroid panels, and assessments for autoimmune or psychiatric symptoms.

Seek urgent medical attention if you experience: sudden chest pain, shortness of breath, a painful or swollen leg, sudden neurologic or vision changes (which could be signs of a blood clot); fever or unusual bleeding; severe depression or suicidal thoughts (specifically for interferon); or painful, non-healing leg ulcers (specifically for HU).

Pregnancy and Family Planning

If you are pregnant, breastfeeding, or planning to conceive, this will heavily influence your choice:

• Hydroxyurea is generally not recommended and is avoided during pregnancy due to teratogenicity (potential risks of birth defects) ^[12]. Product labels also advise against breastfeeding while taking it ^[13].
• Pegylated Interferon is commonly the preferred cytoreductive option when platelet lowering is necessary during pregnancy ^[12][14]. However, pregnancy with ET carries unique risks (such as blood clots and placental issues) and requires close coordination between your hematologist and a high-risk obstetrician ^[15]. Treatment plans often include low-dose aspirin or blood thinners like heparin ^[15].

Disease Modification and Long-Term Outcomes

Because ET is a chronic disease that can theoretically transform into myelofibrosis (bone marrow scarring) or, rarely, leukemia (an acute blood cancer), patients understandably want a drug that prevents this.

Pegylated interferon has been shown to produce a higher rate of molecular response (a laboratory change indicating a reduction in the mutated cells) compared to hydroxyurea ^[4][16]. This means it can reduce the variant allele frequency—the proportion of tested DNA copies in your blood carrying the JAK2, CALR, or MPL driver mutation ^[16]. Some patients on interferon also show improvements in bone marrow scarring ^[17].

However, it is crucial to understand that a molecular response on a lab test does not guarantee a cure, nor does it necessarily translate to better clinical health ^[4]. In the available comparative data, no clear difference has been demonstrated between the two drugs regarding their long-term ability to prevent blood clots or stop the disease from progressing to myelofibrosis or leukemia ^[4]. Both drugs control blood counts similarly well at 12 months ^[4]. Interferon is often considered for younger patients to limit lifelong exposure to hydroxyurea, but neither drug is proven to entirely eliminate the long-term risks of ET ^[3].